Business
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin).
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)\n\nOncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)\n\nBATON ROUGE, LA--(Marketwired - June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH (\"AqVida\"), a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany. As released on 4/26/2017, AqVida granted OncBioMune the rights to several oncology and other generic pharmaceuticals in their portfolio, including imatinib, docetaxel and azathioprine to name a few, for commercialization in the Mexican markets. As an addendum to the agreement, the companies have agreed to expand the portfolio adding Paclitaxel for the treatment of breast, ovarian, lung, bladder, prostate, melanoma, esophageal, Kaposi's sarcoma, as well as other types of solid tumor cancers and Oxaliplatin which is uses to treat colon and rectal cancer that has spread (metastasized). AqVida has commericialized these products for sale in the European markets. AqVida will support OncBioMune's efforts through providing all requisite documentation for seeking marketing approval in Mexico and manufacturing the products at their GMP-certified facility in Germany.Additionally, OncBioMune and AqVida are conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.Furthermore, AqVida has expressed interest in being involved in the development of ProscaVax, OncBioMune's novel therapeutic cancer vaccine currently undergoing clinical trials as a new treatment for prostate cancer. The two companies are contemplating a joint venture in which AqVida would be integral in the clinical development of ProscaVax in Europe, including leading the initiation of ...